Search results
Is It Too Late to Buy Novavax Stock? | The Motley Fool
The Motley Fool· 7 days agoNovavax (NVAX -4.32%) stock is suddenly a buy again this year, with its stock price more than...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 5 hours agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...
Novavax (NASDAQ:NVAX) PT Raised to $18.00
ETF DAILY NEWS· 5 days agoNovavax (NASDAQ:NVAX – Get Free Report) had its target price increased by Bank of America from $12.00 to $18.00 in a research report issued to clients and investors on Friday ...
Novavax seeks FDA nod for updated COVID-19 vaccine By Investing.com
Investing.com· 6 days agoNovavax , Inc. (NASDAQ: NASDAQ:NVAX) has announced its submission for an amended Emergency Use...
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
Fox News· 5 days agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 5 hours agoThat compares to 55.6% for Keytruda alone. Earlier in the year, one analyst called results from the...
3 Short-Squeeze Stocks Ready to Break the Chains of Bearish Sentiment
InvestorPlace· 2 days agoIt was not long ago that Novavax (NASDAQ:NVAX) was among the stocks with high short interest. In the...
FDA recommends COVID jab manufacturers update formulas to combat new strain
BizPac Review· 5 days agoA new strain of COVID has prompted recommendations for vaccine companies to update their formulas in anticipation of cases in the fall. The U.S. Food and Drug Administration (FDA) announced ...
FDA Tells Vaccine Makers to Target New COVID Variant for Fall
WFMZ Eastern Pennsylvania and Western New Jersey· 6 days agoCOVID vaccine makers will be advised to update their shots to target the KP.2 variant, an offshoot...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 6 days agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....